Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82.

Saved in:
Bibliographic Details
Title: Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82.
Authors: Najera SS; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.; Chemical Biology Laboratory, National Cancer Institute, Frederick, Maryland., Ricketts CJ; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Schmidt LS; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Medina JI; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Saito K; Small Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Ileva L; Small Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Brender JR; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., James AM; Animal Research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Peer CJ; Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, Maryland., Gouker B; Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Karim BO; Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Chernova O; Oncotartis, Inc., Buffalo, New York., Wells C; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Wei MH; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Yang Y; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Zhang X; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland., Klumpp-Thomas C; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland., Travers J; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland., Chen L; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland., Wilson KM; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland., Issaq SH; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Figg WD; Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, Maryland., Difilippantonio S; Animal Research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Kalen JD; Small Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Krishna MC; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Thomas CJ; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland., Ceribelli M; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland., Heske CM; Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland., Crooks DR; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Meier JL; Chemical Biology Laboratory, National Cancer Institute, Frederick, Maryland.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2025 Feb 04; Vol. 24 (2), pp. 200-213.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-24-0225